Glucose transporter expression of an esophageal gastrointestinal tumor detected by f-18 FDG PET/CT

Clinical Nuclear Medicine

Volumn 35, Issue 7, 2010, Pages 505-509

  Kaida, Hayato ^a   Ishibashi, Masatoshi ^a   Yuzuriha, Miya ^a   Kurata, Seiji ^a   Arikawa, Syunji ^a   Kawahara, Akihiko ^b   Uozumi, Jun ^a   Uchida, Masafumi ^a   Kobayashi, Maiko ^a   Hirose, Yasumitsu ^a   Fujita, Hiromasa ^a   Kage, Masayoshi ^b   Hayabuchi, Naofumi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY HOSPITAL   (Japan)

Author keywords

esophagus; fluorine 18 fluorodeoxyglucose positron emission tomography computed tomography; gastrointestinal tumor; glucose transporter

Indexed keywords

BIOLOGICAL MARKER; CD34 ANTIGEN; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; STEM CELL FACTOR;

AGED; ARTICLE; ASPIRATION BIOPSY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; DRUG ACCUMULATION; DRUG UPTAKE; ENDOSCOPIC ECHOGRAPHY; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; FEMALE; FOLLOW UP; GASTROINTESTINAL RADIOGRAPHY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TREATMENT OUTCOME; WHOLE BODY IMAGING;

AGED; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 77954023486     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181e05d79     Document Type: Article

References (19)

1. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal tumor show phenotypic characteristic of the intestinal cells of Cajal. Am J Pathol. 1998;152:1259-1269.
2. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal storomal tumors: a consensus approach. Hum Pathol. 2002;33:459-465. (Pubitemid 34747864)
3. Sarllomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD 34. Mod Pathol. 1998;11:728-734.
4. Van den Abbeele AD. The lessons of GIST-PET and PET/CT: a new paradigm for imaging. Oncologist. 2008;13(suppl 2):8-13.
5. Kamiyama Y, Aihara R, Nakabayashi T, et al. 18F-fluorodeoxyglucose positron emission tomography:useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg. 2005;29:1429-1435.
6. Kaneta T, Takahashi S, Fukuda H, et al. Clinical significance of performing 18F-FDG-PET on patients with gastrointestinal stromal tumors: a summary of a Japanese multicenter study. Ann Nucl Med. 2009;23:459-464.
7. Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in line PET/CT in patients with gastrointestinal stromal tumors: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging. 2005;32: 153-162.
8. Holdsworth CH, Badawi RD, Manola JB, et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. Am J Roentgenol. 2007;189:324-330.
9. Lau S, Lui CY, Yeung YP, et al. Gastrointestinal stromal tumor of rectum: a report of 2 cases. J Comput Assist Tomogr. 2003;27:609-615.
10. Portale G, Zaninotto G, Costantini M, et al. Esophageal GIST: case report of surgical enucleation and update on current diagnostic and therapeutic options. Int J Surg Pathol. 2007;15:393-396.
11. Blum MG, Bilimoria KY, Wayne JD, et al. Surgical consideration for the management and resection of esophageal gastrointestinal stromal tumors. Ann Thorac Surg. 2007;84:1717-1723.
12. Chang WC, Tzao C, Shen DH, et al. Gastrointestinal stromal tumor (GIST) of the esophagus detected by positron emission tomography/computed tomography. Dig Dis Sci. 2005;50:1315-1318.
13. de Geus-Oei LF, van Krieken JH, Aliredjo RP, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer. 2007;55: 79-87.
14. Tian M, Zhang H, Nakasone Y, et al. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging. 2004;31:5-12.
15. Paudyal B, Paudyal P, Oriuchi N, et al. Clinical implication of glucose transporter and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma. Int J Oncol. 2008;33:1047-1054.
16. Shim HK, Lee WW, Park SY, et al. Expression of glucose transporter types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkins lymphoma. Nucl Med Biol. 2009;36:191-197.
17. Tarn C, Skorobogatko YV, Taguchi T, et al. Therapeutic effect of Imatinib in gastrointestinal stromal tumor: AKT signaling dependent and independent mechanism. Cancer Res. 2006;66:5477-5486.
18. Rubin BP, Heinrich M, Corless CL. Gastrointestinal stromal tumor. Lancet. 2007;369:1731-1741.
19. Sasaki-Suzuki N, Arai K, Ogata T, et al. Growth hormone inhibition of glucose uptake in adipocytes occurs without affecting GLUT-4 translocation through an insulin receptor substrate-2-phosphatidylinositol 3-kinase-dependent pathway. J Biom Chem. 2009;284:6061-6070.